Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- RaQualia Licenses 5-HT4 Partial Agonist to CJ CheilJedang in South Korea
August 8, 2011
- Fujifilm, DRL Announce Plans to Establish Generic Drugs JV in Japan
August 8, 2011
- Astellas Transfers Investigational Anti-arrhythmic Agent to Merck Subsidiary
August 8, 2011
- Revision Proposed to 70% Rule for Pricing of New Generics
August 8, 2011
- Teijin Pharma's Gout Agent Febuxostat Launched in South Korea
August 8, 2011
- Korosho Orders 10-Day Suspension of Operations for Kobayashi Medical
August 8, 2011
- M3 to Promote Clinical Study Support Business by Acquiring SMO
August 8, 2011
- Roche to File for mBC Treatment Pertuzumab in Japan in 2012
August 8, 2011
- Korosho to Publish JAMS's Opinions on Switch OTC Drug Candidates Sometime in August
August 8, 2011
- Chuikyo to Assess Impact of “Premium for Development of New Drugs”
August 8, 2011
- Millennium Submits sNDA for Velcade in US
August 8, 2011
- Axitinib to Be Used in 3rd-line Therapy for RCC: Kantar Health
August 8, 2011
- Revisions Proposed to Re-pricing Rule, Adjustment Based on Average Overseas Prices
August 8, 2011
- US FDA Issues Refusal to File Letter for Eisai's Perampanel
August 8, 2011
- “Dispensing Point”System Contributing to Higher Average Price per Prescription: GROWELL
August 8, 2011
- Proemend, Teribone Recommended for Approval
August 8, 2011
- Application for Zonegran Monotherapy for Epilepsy Accepted in Europe: Eisai
August 8, 2011
- JAS to Assess Risk Factors Based on Absolute Risk in Its Revised GLs for Prevention of AD
August 8, 2011
- Recommendation for Approval Withheld for Avastin for Breast Cancer
August 8, 2011
- SUEVEY
August 8, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…